Mangalam Drugs and Organics Shows Strong Financial Growth, Surpasses Previous Year's PAT in Just Half a Year

Mangalam Drugs and Organics, a microcap pharmaceutical company, has recently announced its financial results for the quarter ending September 2024. The company has shown positive growth in its financial performance, with its score improving from 8 to 9 in the last 3 months according to MarketsMOJO.

One of the key highlights of the financial report is the significant growth in Profit After Tax (PAT) for the half-yearly period, which has increased by 140.99% year on year. This is a very positive trend for the company and shows its strong financial performance. In fact, the company has already surpassed its PAT for the previous twelve months in just half a year.

However, the company has also seen a decline in its net sales for the quarter, which has fallen by -10.6% compared to the average net sales of the previous four quarters. This is a near-term negative trend for the company.

Despite this, MarketsMOJO has given a 'Hold' call for Mangalam Drugs, indicating that the company's stock is expected to perform steadily in the near future. With its positive financial performance and strong growth potential in the pharmaceutical industry, Mangalam Drugs and Organics is definitely a company to watch out for in the microcap segment.